Jefferies Maintains Buy on Apogee Therapeutics, Raises Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Akash Tewari has maintained a Buy rating on Apogee Therapeutics (NASDAQ:APGE) and increased the price target from $37 to $75.

March 06, 2024 | 2:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies has maintained a Buy rating on Apogee Therapeutics and raised the price target from $37 to $75.
The upgrade in the price target by a reputable analyst like Akash Tewari from Jefferies is a strong positive signal for Apogee Therapeutics. It suggests a bullish outlook on the stock, likely due to underlying strengths or anticipated performance improvements. This can lead to increased investor confidence and potential upward movement in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100